Lonza Group AG (FRA:LO3)
Germany · Delayed Price · Currency is EUR 606.20
-12.20 (-1.97%)
At close: Aug 1, 2025
Revenue by Product
Fiscal year is January - December.
Year Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | NaN - NaN |
|---|---|---|---|---|---|---|
Integrated Biologics | 3.68B | Log In | Log In | Log In | Log In | Upgrade |
Integrated Biologics Growth | 14.89% | Log In | Log In | Log In | Log In | Upgrade |
Advanced Synthesis | 983.00M | Log In | Log In | Log In | Log In | Upgrade |
Advanced Synthesis Growth | 44.77% | Log In | Log In | Log In | Log In | Upgrade |
Specialized Modalities | 689.00M | Log In | Log In | Log In | Log In | Upgrade |
Specialized Modalities Growth | 22.47% | Log In | Log In | Log In | Log In | Upgrade |
Capsules & Health Ingredients | 1.05B | Log In | Log In | Log In | Log In | Upgrade |
Capsules & Health Ingredients Growth | -12.99% | Log In | Log In | Log In | Log In | Upgrade |
Corporate | 172.00M | Log In | Log In | Log In | Log In | Upgrade |
Corporate Growth | -7.56% | Log In | Log In | Log In | Log In | Upgrade |
EBITDA by Product
Fiscal year is January - December.
Year Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | NaN - NaN |
|---|---|---|---|---|---|---|
Integrated Biologics Core EBITDA | 1.27B | Log In | Log In | Log In | Log In | Upgrade |
Integrated Biologics Core EBITDA Growth | 16.34% | Log In | Log In | Log In | Log In | Upgrade |
Advanced Synthesis Core EBITDA | 351.00M | Log In | Log In | Log In | Log In | Upgrade |
Advanced Synthesis Core EBITDA Growth | 64.55% | Log In | Log In | Log In | Log In | Upgrade |
Specialized Modalities Core EBITDA | 108.00M | Log In | Log In | Log In | Log In | Upgrade |
Specialized Modalities Core EBITDA Growth | -1.59% | Log In | Log In | Log In | Log In | Upgrade |
Capsules & Health Ingredients Core EBITDA | 256.00M | Log In | Log In | Log In | Log In | Upgrade |
Capsules & Health Ingredients Core EBITDA Growth | -34.28% | Log In | Log In | Log In | Log In | Upgrade |
Corporate Core EBITDA | -73.00M | Log In | Log In | Log In | Log In | Upgrade |
Corporate Core EBITDA Growth | 151.52% | Log In | Log In | Log In | Log In | Upgrade |
Revenue by Geography
Fiscal year is January - December.
Year Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | NaN - NaN |
|---|---|---|---|---|---|---|
Europe | 3.14B | Log In | Log In | Log In | Log In | Upgrade |
Europe Growth | - | Log In | Log In | Log In | Log In | Upgrade |
North and Central America | 2.44B | Log In | Log In | Log In | Log In | Upgrade |
North and Central America Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Latin America | 129.00M | Log In | Log In | Log In | Log In | Upgrade |
Latin America Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Asia | 837.00M | Log In | Log In | Log In | Log In | Upgrade |
Asia Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Australia & New Zealand | 17.00M | Log In | Log In | Log In | Log In | Upgrade |
Australia & New Zealand Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Other Geographic | 3.00M | Log In | Log In | Log In | Log In | Upgrade |
Other Geographic Growth | - | Log In | Log In | Log In | Log In | Upgrade |